U.S. flag

An official website of the United States government

NM_002764.4(PRPS1):c.705-11T>C AND multiple conditions

Germline classification:
Likely benign (1 submission)
Last evaluated:
Jan 7, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002495966.1

Allele description [Variation Report for NM_002764.4(PRPS1):c.705-11T>C]

NM_002764.4(PRPS1):c.705-11T>C

Gene:
PRPS1:phosphoribosyl pyrophosphate synthetase 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Xq22.3
Genomic location:
Preferred name:
NM_002764.4(PRPS1):c.705-11T>C
HGVS:
  • NC_000023.11:g.107647595T>C
  • NG_008407.1:g.24172T>C
  • NM_001204402.2:c.93-11T>C
  • NM_002764.4:c.705-11T>CMANE SELECT
  • LRG_264:g.24172T>C
  • NC_000023.10:g.106890825T>C
Links:
dbSNP: rs190164271
NCBI 1000 Genomes Browser:
rs190164271
Molecular consequence:
  • NM_001204402.2:c.93-11T>C - intron variant - [Sequence Ontology: SO:0001627]
  • NM_002764.4:c.705-11T>C - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Name:
Arts syndrome (ARTS)
Synonyms:
X-linked fatal ataxia with deafness and loss of vision; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0010533; MedGen: C0796028; Orphanet: 1187; OMIM: 301835
Name:
Hearing loss, X-linked 1
Synonyms:
DEAFNESS, X-LINKED 2, SENSORINEURAL CONGENITAL; Deafness, X-linked 1; DFNX1 Nonsyndromic Hearing Loss and Deafness
Identifiers:
MONDO: MONDO:0010577; MedGen: C1844677; Orphanet: 90625; OMIM: 304500
Name:
Charcot-Marie-Tooth disease X-linked recessive 5
Synonyms:
OPTIC ATROPHY, POLYNEUROPATHY, AND DEAFNESS; Rosenberg Chutorian syndrome; Optic atrophy, sensorineural hearing loss and polyneuropathy; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0010699; MedGen: C1839566; OMIM: 311070
Name:
Phosphoribosylpyrophosphate synthetase superactivity
Identifiers:
MONDO: MONDO:0010395; MedGen: C1970827; Orphanet: 3222; OMIM: 300661

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV002796203Fulgent Genetics, Fulgent Genetics
criteria provided, single submitter

(ACMG Guidelines, 2015)		Likely benign
(Jan 7, 2022) 		unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee.

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Fulgent Genetics, Fulgent Genetics, SCV002796203.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jan 13, 2025